Zomedica Announces Interim Closing and Extension of Its Private Offering of Common Shares
June 28 2018 - 8:57PM
Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM) (the
“Company”), a veterinary diagnostic and pharmaceutical company,
announced today that it has effected an interim closing of its
previously announced private offering of common shares, resulting
in the sale of 1,605,812 common shares for gross proceeds of
$3,452,496 (C$4,415,983). As previously announced, the Company is
offering an aggregate of up to 4,651,162 common shares at a price
of $2.15 (C$2.75) per share for aggregate gross proceeds of up to
$10,000,000 (C$12,790,700) in the United States to accredited
investors only pursuant to the exemption from registration provided
by Section 4(a)(2) of the Securities Act of 1933, as amended (the
“Securities Act”), and Rule 506(b) of Regulation D thereunder. The
offering is also being made in Canada in accordance with applicable
Canadian securities laws.
Including the shares sold today, the Company has sold an
aggregate of 1,861,627 common shares for gross proceeds of
approximately $4,002,500 (C$5,119,475) in the offering. All of the
common shares sold in the offering will be subject to a statutory
four-month hold period in accordance with applicable Canadian
securities laws, which will expire on October 29, 2018 in the case
of the shares sold today.
The Company also announced that it has extended the expiration
date of the offering to July 28, 2018. The Company intends to use
the net proceeds of the offering for working capital and general
corporate purposes, including the ongoing development of its
product candidates.
The common shares have not been registered under the Securities
Act and may not be offered or sold in the United States absent
registration or an applicable exemption from such registration
requirements. About ZomedicaBased in Ann Arbor,
Michigan, Zomedica (NYSE American:ZOM) (TSX-V:ZOM) is a veterinary
diagnostic and pharmaceutical company creating products for
companion animals (canine, feline and equine) by focusing on the
unmet needs of clinical veterinarians. Zomedica’s product portfolio
will include novel diagnostics and innovative therapeutics that
emphasize patient health and practice health. With a team that
includes clinical veterinary professionals, it is Zomedica’s
mission to give veterinarians the opportunity to lower costs,
increase productivity, and grow revenue while better serving the
animals in their care. For more information, visit
www.ZOMEDICA.com.
Follow Zomedica
- Email Alerts: http://investors.zomedica.com
- LinkedIn: https://www.linkedin.com/company/zomedica
- Facebook: https://www.facebook.com/zomedica/
- Twitter: https://twitter.com/zomedica
Reader Advisory Neither TSX Venture Exchange
nor its Regulation Services Provider (as that term is defined in
the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of the release.
Except for statements of historical fact, this news release
contains certain "forward-looking information" within the meaning
of applicable securities law. Forward-looking information is
frequently characterized by words such as "plan", "expect",
"project", "intend", "believe", "anticipate", "estimate" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. Although we believe that the expectations
reflected in the forward-looking information are reasonable, there
can be no assurance that such expectations will prove to be
correct. We cannot guarantee future results, performance or
achievements. Consequently, there is no representation that the
actual results achieved will be the same, in whole or in part, as
those set out in the forward-looking information.
Forward-looking information is based on the opinions and
estimates of management at the date the statements are made, and
are subject to a variety of risks and uncertainties and other
factors that could cause actual events or results to differ
materially from those anticipated in the forward-looking
information. Some of the risks and other factors that could cause
the results to differ materially from those expressed in the
forward-looking information include, but are not limited to: the
risk that the Company will be able to sell all of the common shares
in the offering, the risk that the success of the offering will be
subject to market conditions, the risk that closing of the offering
will be subject to certain conditions and there can be no
assurances that the conditions will be satisfied, and the risk that
the offering will not close by the intended date. Readers are
cautioned that this list of risk factors should not be construed as
exhaustive.
The forward-looking information contained in this news release
is expressly qualified by this cautionary statement. We undertake
no duty to update any of the forward-looking information to conform
such information to actual results or to changes in our
expectations except as otherwise required by applicable securities
legislation. Readers are cautioned not to place undue reliance on
forward-looking information.
Investor Relations ContactsShameze Rampertab,
CPA, CAsrampertab@zomedica.com+1 647.283.3630
PCG Advisory GroupKirin Smith, COOksmith@pcgadvisory.com+1
646.863.6519www.pcgadvisory.com
Zomedica Pharmaceuticals (TSXV:ZOM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zomedica Pharmaceuticals (TSXV:ZOM)
Historical Stock Chart
From Apr 2023 to Apr 2024